Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Naturlose (D-Tagatose) Efficacy Evaluation Trial (NEET)

This study has been completed.
Sponsor:
Collaborator:
University of Kentucky
Information provided by (Responsible Party):
Robert Lodder, Spherix Incorporated
ClinicalTrials.gov Identifier:
NCT00955747
First received: August 7, 2009
Last updated: November 18, 2014
Last verified: November 2014
Results First Received: December 5, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Type 2 Diabetes
Interventions: Drug: Tagatose
Drug: Sugar Substitute Splenda

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited in site physicians' offices.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Patients participated in an eight week run-in period during which diabetes education was provided and diet and exercise were stabilized.

Reporting Groups
  Description
Sugar Substitute Splenda 1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
Tagatose 15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment

Participant Flow:   Overall Study
    Sugar Substitute Splenda     Tagatose  
STARTED     253     241  
COMPLETED     184     172  
NOT COMPLETED     69     69  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sugar Substitute Splenda 1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
Tagatose 15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment
Total Total of all reporting groups

Baseline Measures
    Sugar Substitute Splenda     Tagatose     Total  
Number of Participants  
[units: participants]
  184     172     356  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     160     152     312  
>=65 years     24     20     44  
Age  
[units: years]
Mean ± Standard Deviation
  51.6  ± 11.0     51.7  ± 9.7     51.7  ± 10.4  
Gender  
[units: participants]
     
Female     95     91     186  
Male     89     81     170  
Region of Enrollment  
[units: participants]
     
United States     48     52     100  
India     136     120     256  



  Outcome Measures

1.  Primary:   Change in Hemoglobin A1C Level From Baseline   [ Time Frame: 1 year from baseline ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Robert Lodder
Organization: University of Kentucky
phone: 859-955-0845
e-mail: lodder@uky.edu


No publications provided


Responsible Party: Robert Lodder, Spherix Incorporated
ClinicalTrials.gov Identifier: NCT00955747     History of Changes
Obsolete Identifiers: NCT00451477
Other Study ID Numbers: 70971-004
Study First Received: August 7, 2009
Results First Received: December 5, 2013
Last Updated: November 18, 2014
Health Authority: United States: Food and Drug Administration